One of the main concerns with Enterococcus in cancer therapy is its ability to develop resistance to multiple antibiotics. This includes resistance to vancomycin, an antibiotic often used as a last resort. Vancomycin-resistant Enterococci (VRE) are particularly problematic because they limit the options available for effective treatment. Infections caused by VRE can be difficult to manage and may lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates.
